Capricor Therapeutics has been issued a Form 483 following an FDA inspection of its manufacturing facility, citing several observations primarily related to quality systems and documentation. While the company maintains these findings do not require major changes to cGMP processes, the regulatory scrutiny injects uncertainty into its Duchenne Muscular Dystrophy cell therapy program's approval timeline and commercial prospects.